Reduced LPA-LPAR1-dependent signaling is associated with beneficial effects in many pulmonary diseases, including lung fibrosis, LPS-induced inflammation, bronchoconstriction, airway hyper-responsiveness, and (experimental) BPD (Toews et al., 2002; Tager et al., 2008; Swaney et al., 2010; Zhao et al., 2011; Chen et al., 2016), demonstrating the therapeutic potential of LPAR1 inhibition in adult and neonatal lung disease, including BPD. The gene discussed is LPAR1; the disease is bronchopulmonary dysplasia.